ong-term Follow-up of patients participants with pemphigus From Study RITUXIMAB3
Phase 1
- Conditions
- Patients with Bullous pemphigoid included in RITUXIMAB3 studyMedDRA version: 20.0Level: LLTClassification code 10006567Term: Bullous pemphigoidSystem Organ Class: 100000004858Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]
- Registration Number
- EUCTR2018-001417-32-FR
- Lead Sponsor
- CHU-Hôpitaux de Rouen
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- All
- Target Recruitment
- 77
Inclusion Criteria
Patient included in RITXIMAB3 study
Patient having read and understood the information letter and signed the Informed Consent Form
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 17
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 60
Exclusion Criteria
Person deprived of liberty by administrative or judicial decision
Person placed under judicial protection
Person under guardianship or supervision
Women pregnant or lactating
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method